ArticleMolecular genetics and genomics : MGG2026
Equity-aware variant interpretation needs local allele frequencies and calibrated functional evidence: comment on Bianco & Planello (2025).
Article in Molecular genetics and genomics : MGG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Equitable hereditary‑cancer genomics requires variant interpretation that performs reliably in under‑represented and admixed populations-not only in well‑sampled European cohorts. Building on Bianco and Planello (2025), this Comment outlines an equity‑by‑design workflow that couples regional allele‑frequency baselines (e.g., GenomeIndia, IndiGenomes, ABraOM) with calibrated functional evidence from saturation genome editing and related multiplex assays, implemented within updated ClinGen/ACMG‑AMP Bayesian point‑based frameworks. The pipeline defines sub‑national AF strata, quantifies AF uncertainty, maps quantitative functional readouts to PS3/BS3 strengths, and integrates AF, functional, in‑silico and clinical signals with transparent scoring while tracking fairness metrics (e.g., VUS rate ratios) and using patient‑centered reporting language. Overall, routinely combining local population priors with decision‑grade functional likelihoods provides a practical, auditable pathway to reduce VUS disparities and strengthen the global validity of clinical genomic interpretation.
Indexed as
Identifiers
41559235What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.